

# PRIOR AUTHORIZATION CRITERIA

<b>BRAND NAME (generic)</b>	<b>NAGLAZYME (galsulfase)</b>	
<b>Status: CVS Caremark Criteria</b>		<b>MDC</b>
<b>Type: Initial Prior Authorization</b>		<b>Ref #577-A</b>

## FDA-APPROVED INDICATION<sup>1</sup>

Naglazyme is indicated for patients with Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome). Naglazyme has been shown to improve walking and stair-climbing capacity.

## CRITERIA FOR APPROVAL

1	Does the patient have a diagnosis of mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)? [If no, no further questions.]	Yes	No
2	Was the diagnosis confirmed by an enzyme assay demonstrating a deficiency of N-acetylgalactosamine 4-sulfatase (arylsulfatase B) enzyme activity OR by genetic testing?	Yes	No

## Guidelines for Approval

<b>Duration of Approval</b>		<b>12 Months</b>
<b>Set 1: MPS VI</b>		
<b>Yes to question(s)</b>		<b>No to question(s)</b>
1		None
2		

## Mapping Instructions

	<b>Yes</b>	<b>No</b>
1	Go to 2	Deny
2	Approve, 12 months	Deny

## RATIONALE

These criteria meet the Medicare Part D definition of a medically accepted indication. This definition includes uses which are approved by the FDA or supported by a citation included, or approved for inclusion, in one of the Medicare approved compendia.

The intent of the criteria is to ensure that patients follow selection elements noted in labeling and/or practice guidelines in order to decrease the potential for inappropriate utilization.

## REFERENCES

1. Naglazyme [package insert]. Novato, CA: BioMarin Pharmaceutical, Inc.; March 2013.

## DOCUMENT HISTORY

Written: Specialty Clinical Development (AC) 11/2009  
 Revised: KR 08/2010; TG 07/2011, 09/2011 (CMS); AC 09/2012 (CMS); AS 09/2013 (CMS), IP 04/2014, 09/2014 (CMS), TS 04/2015, IP 08/2015 (CMS), TS 06/2016 (CMS), DK 04/2016, 07/2017 (CMS)  
 Reviewed: CDPR/WLF 12/2009; KP 08/2010, 08/2011; DNC 07/2012, 06/2013; SES 04/2014, LCB 04/2015, ME 05/2016  
 External Review: 01/2010, 09/2010, 08/2011, 08/2012, 07/2013, 06/2014, 05/2015, 07/2016

Naglazyme 577-A MDC 2018 (1).docx

© 2017 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.